These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Intratumoral administration of a 1,2-dimyristyloxypropyl-3- dimethylhydroxyethyl ammonium bromide/dioleoylphosphatidylethanolamine formulation of the human interleukin-2 gene in the treatment of metastatic renal cell carcinoma. Galanis E; Burch PA; Richardson RL; Lewis B; Pitot HC; Frytak S; Spier C; Akporiaye ET; Peethambaram PP; Kaur JS; Okuno SH; Unni KK; Rubin J Cancer; 2004 Dec; 101(11):2557-66. PubMed ID: 15517589 [TBL] [Abstract][Full Text] [Related]
25. Exploring immune therapy for renal cancer. Matsushita H; Kakimi K; Tomita Y; Tatsugami K; Naito S; Suekane S; Noguchi M; Moriya F; Matsuoka K; Itoh K; Kobayashi H; Eto M; Takahashi W; Kawano Y; Wada Y Int J Urol; 2011 Jun; 18(6):412-21. PubMed ID: 21599759 [No Abstract] [Full Text] [Related]
26. Immunotherapy for renal cell cancer. Yang JC; Childs R J Clin Oncol; 2006 Dec; 24(35):5576-83. PubMed ID: 17158543 [TBL] [Abstract][Full Text] [Related]
27. Recent developments in renal cell cancer immunotherapy. Wysocki PJ; Zolnierek J; Szczylik C; Mackiewicz A Expert Opin Biol Ther; 2007 May; 7(5):727-37. PubMed ID: 17477809 [TBL] [Abstract][Full Text] [Related]
28. [Efficacy of autologous renal tumor cell lysate-loaded dendritic cell vaccine in combination with cytokine-induced killer cells on advanced renal cell carcinoma--a report of ten cases]. Wang H; Zhou FJ; Wang QJ; Qin ZK; Huang LX; Liu ZW; Han H; Li YQ; Chen SP; Xia JC Ai Zheng; 2006 May; 25(5):625-30. PubMed ID: 16687087 [TBL] [Abstract][Full Text] [Related]
29. New therapeutic developments in renal cell cancer. Prenen H; Gil T; Awada A Crit Rev Oncol Hematol; 2009 Jan; 69(1):56-63. PubMed ID: 18752971 [TBL] [Abstract][Full Text] [Related]
30. Antitumor effect on murine renal cell carcinoma by autologous tumor vaccines genetically modified with granulocyte-macrophage colony-stimulating factor and interleukin-6 cells. Kinoshita Y; Kono T; Yasumoto R; Kishimoto T; Wang CY; Haas GP; Nishisaka N J Immunother; 2001; 24(3):205-11. PubMed ID: 11394497 [TBL] [Abstract][Full Text] [Related]
31. Synergy between dendritic cells and GM-CSF-secreting tumor cells for the treatment of a murine renal cell carcinoma. Driessens G; Hoffmann P; Pouwels M; Zlotta A; Schulman C; Velu T; Bruyns CA J Immunother; 2009; 32(2):140-4. PubMed ID: 19238012 [TBL] [Abstract][Full Text] [Related]
32. Medical treatment options in patients with metastatic renal cell carcinoma. Haferkamp A; Hohenfellner M Nephrol Dial Transplant; 2007 Apr; 22(4):996-9. PubMed ID: 17210591 [No Abstract] [Full Text] [Related]
33. The use of monoclonal antibody G250 in the therapy of renal-cell carcinoma. Oosterwijk E; Debruyne FM; Schalken JA Semin Oncol; 1995 Feb; 22(1):34-41. PubMed ID: 7855618 [No Abstract] [Full Text] [Related]
34. The role of molecular markers in the staging of renal cell carcinoma. Leppert JT; Pantuck AJ; Figlin RA; Belldegrun AS BJU Int; 2007 May; 99(5 Pt B):1208-11. PubMed ID: 17441912 [No Abstract] [Full Text] [Related]
35. [Cancer of the kidney in the adult]. Delord JP; Alexandre J; Chevreau C; Escudier B Bull Cancer; 1998 Sep; (1 Suppl):4-15. PubMed ID: 9817068 [TBL] [Abstract][Full Text] [Related]